Journal article

Imaging DNA damage response by γH2AX <i>in vivo</i> predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome

Abstract:: Dual isotope SPECT imaging can provide individualized tumor dose-responses that can be used to predict lutetium-177 treatment efficacy. This bio-dosimeter metric appears to be dependent upon the extent of senescence induction and suggests an integral role that senescence plays in lutetium-177 treatment efficacy.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

O'Neill, E., Mosley, M., & Cornelissen, B. (2023). Imaging DNA damage response by γH2AX <i>in vivo</i> predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome. Theranostics, 13(4), 1302–1310.

MLA Style

O'Neill, E, et al. “Imaging DNA Damage Response by γH2AX <i>in Vivo</i> Predicts Treatment Response to Lutetium-177 Radioligand Therapy and Suggests Senescence as a Therapeutically Desirable Outcome.” Theranostics, vol. 13, no. 4, 2023, pp. 1302–10.

Chicago Style

O'Neill, E, M Mosley, and B Cornelissen. 2023. “Imaging DNA Damage Response by γH2AX <i>in Vivo</i> Predicts Treatment Response to Lutetium-177 Radioligand Therapy and Suggests Senescence as a Therapeutically Desirable Outcome.” Theranostics 13 (4): 1302–10.
Print

Access Document

Files:: ONeill_et_al_2023_Imaging_DNA_damage.pdf

(Preview, Version of record, pdf, 3.3MB, Terms of use)

Publisher copy:: 10.7150/thno.82101

Authors

+ O'Neill, E More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0002-7987-8160

+ Mosley, M More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0002-5324-4565

+ Cornelissen, B More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0001-7581-3303

Publisher:: Ivyspring International Publisher
Journal:: Theranostics More from this journal
Volume:: 13
Issue:: 4
Pages:: 1302-1310
Publication date:: 2023-02-21
DOI:: 10.7150/thno.82101
EISSN:: 1838-7640
ISSN:: 1838-7640

Language:: English
Keywords:: Medicine

Radionuclide therapy

Chemistry

Cancer research

Ex vivo

Biology

Internal medicine

Apoptosis

Prostate cancer

DNA

In vivo

Clonogenic assay

Senescence

Nuclear medicine

Cancer

DNA damage

In vitro
Pubs id:: 1334129
Local pid:: pubs:1334129
Source identifiers:: W4324009868
Deposit date:: 2026-05-05
ARK identifier:: ark:/29072/ora_579ad057a587467c9a0c31058fe8ae1e

Terms of use

Copyright date:: 2023

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP